Defining Novel Molecular Pathways to Totipotency
定义全能性的新分子途径
基本信息
- 批准号:10219317
- 负责人:
- 金额:$ 32.94万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-24 至 2023-06-30
- 项目状态:已结题
- 来源:
- 关键词:ATAC-seqAnimal ExperimentationBindingCCL3 geneCell Culture TechniquesCellsChromatinCodeComplexConceptusDataDevelopmentElementsEmbryoEmbryonic DevelopmentEndogenous RetrovirusesGenerationsGenesGenetic TranscriptionIn VitroIndividualKnowledgeLengthMessenger RNAMicroRNAsMolecularMusOrganOrganismPathway interactionsPluripotent Stem CellsProductionProteinsProteomeProteomicsRNARegulator GenesRegulatory ElementReporterReportingRoleSourceSuggestionTestingTherapeuticTimeTotipotencyTotipotentTotipotent cellUntranslated RNAbaseembryo cellembryo stage 2embryonic stem cellgag-pol Fusion Proteinsin vitro Modelin vivonovelpluripotency factorself-renewalsmall molecule inhibitorstemstem cellstranscriptometransplantation therapyzygote
项目摘要
PROJECT SUMMARY
Totipotency, a remarkable cellular plasticity of a single cell in generating a complete organism with both
embryonic and extraembryonic contribution, is essential for multicellularity and development. In mice, fully
totipotent cells exist transiently in the zygote and cleavage-stage blastomeres, although totipotent 2-cell (2C)-
like cells (2CLCs) can also arise sporadically or induced genetically in cultured embryonic stem cell (ESCs)
that are pluripotent and can only contribute to embryonic lineages. Recently, expanded potential stem cells and
extended pluripotent stem cells, collectively known as EPSCs, with totipotency features were derived and
stably cultured in vitro using two distinct sets of small molecule inhibitors. However, 2CLCs and the two EPSC
lines differ in their culture conditions, transcriptomes, and expression of core pluripotency factors, suggestive of
alternative totipotent states. 2CLCs and EPSCs represent easily accessible cell source and valuable in vitro
models for understanding totipotency, the knowledge of which will be critical to capture and stabilize the
totipotent 2CLC state, which is not currently possible. Defining molecular pathways underlying these various
totipotent cells will facilitate unraveling the complex regulatory mechanisms of totipotency and achieving the
capture/stabilization of totipotent 2CLCs. The totipotent 2CLCs were reported to reactivate transcription of
endogenous retroviruses (ERVs), in particular MERVL, whose activation has now been found to be causative
for totipotency in our preliminary studies. ZSCAN4 is also sharply expressed in 2C-stage embryo and marks
those sporadic ESCs exiting from the ESC state towards 2CLCs. By characterizing MERVL/ZSCAN4 double
reporter positive (DR+/+) ESCs, we have begun to dissect the molecular pathways underlying 2CLC
totipotency and discovered miR-344 and its direct target ZMYM2 as novel positive and negative regulators,
respectively, for MERVL activation and 2CLC totipotency. The objective of this application is to extend our
knowledge of the divergent cellular potency states in ESC culture, and define the MERVL contribution to
totipotency and explore transcriptional and post-transcriptional mechanisms underlying totipotency. We
hypothesize that 2CLCs represent an alternative totipotent state that is regulated by a novel molecular axis
encompassing the transcriptional and post-transcriptional mechanisms. We propose the following studies to
test our hypothesis. 1) Define a molecular roadmap for alternative totipotent states in EPSCs and 2CLCs. 2)
Establish the functional contribution of MERVL elements to 2CLC totipotency. We will define and distinguish
functional roles of individual MERVL elements in contributing to 2CLC totipotency. 3) Dissect the molecular
mechanism underlying 2CLC totipotency by establishing miR-344 as a new paradigm for understanding
mammalian totipotency. Understanding the molecular mechanisms that drive and induce totipotent features in
vitro is essential to understanding of how a maximum degree of cellular plasticity can be achieved and
maintained, thereby providing more options for efficient reprogramming and potential therapeutic avenues.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jianlong Wang其他文献
Jianlong Wang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jianlong Wang', 18)}}的其他基金
TET2-mediated transcriptional and epigenetic control of normal and malignant hematopoiesis
TET2介导的正常和恶性造血的转录和表观遗传控制
- 批准号:
10071608 - 财政年份:2019
- 资助金额:
$ 32.94万 - 项目类别:
TET2-mediated transcriptional and epigenetic control of normal and malignant hematopoiesis
TET2介导的正常和恶性造血的转录和表观遗传控制
- 批准号:
9922386 - 财政年份:2019
- 资助金额:
$ 32.94万 - 项目类别:
TET2-mediated transcriptional and epigenetic control of normal and malignant hematopoiesis
TET2介导的正常和恶性造血的转录和表观遗传控制
- 批准号:
10377330 - 财政年份:2019
- 资助金额:
$ 32.94万 - 项目类别:
Defining Molecular Pathways to Expanded Puripotentiality
定义扩展纯潜能的分子途径
- 批准号:
9792267 - 财政年份:2018
- 资助金额:
$ 32.94万 - 项目类别:
RNA-dependent chromatin targeting of TET2 for endogenous retrovirus control in pluripotent stem cells
TET2 的 RNA 依赖性染色质靶向用于多能干细胞中的内源逆转录病毒控制
- 批准号:
10401429 - 财政年份:2018
- 资助金额:
$ 32.94万 - 项目类别:
RNA-dependent chromatin targeting of TET2 for endogenous retrovirus control in pluripotent stem cells
TET2 的 RNA 依赖性染色质靶向用于多能干细胞中的内源逆转录病毒控制
- 批准号:
10176171 - 财政年份:2018
- 资助金额:
$ 32.94万 - 项目类别:
Defining Novel Molecular Pathways to Totipotency
定义全能性的新分子途径
- 批准号:
10428542 - 财政年份:2018
- 资助金额:
$ 32.94万 - 项目类别:
RNA-dependent chromatin targeting of TET2 for endogenous retrovirus control
TET2 的 RNA 依赖性染色质靶向用于内源性逆转录病毒控制
- 批准号:
9767845 - 财政年份:2018
- 资助金额:
$ 32.94万 - 项目类别:
Transcriptional and Epigenetic Control of Pluripotency and Development by Zfp281
Zfp281 对多能性和发育的转录和表观遗传控制
- 批准号:
10102033 - 财政年份:2018
- 资助金额:
$ 32.94万 - 项目类别:
相似海外基金
Development of a Drosophila-based platform to replace and reduce animal experimentation in epilepsy research
开发基于果蝇的平台来取代和减少癫痫研究中的动物实验
- 批准号:
NC/V001051/1 - 财政年份:2020
- 资助金额:
$ 32.94万 - 项目类别:
Research Grant
Doctoral Dissertation Research: Ethical Issues in Animal Experimentation
博士论文研究:动物实验的伦理问题
- 批准号:
1424484 - 财政年份:2014
- 资助金额:
$ 32.94万 - 项目类别:
Standard Grant
Tissue formation involving stem/progenitor cell research and animal experimentation (N01)
涉及干/祖细胞研究和动物实验的组织形成(N01)
- 批准号:
30245585 - 财政年份:2006
- 资助金额:
$ 32.94万 - 项目类别:
Collaborative Research Centres
Animal Experimentation system as an infrastructure to support translational progression of diabetes research to medical practice
动物实验系统作为支持糖尿病研究向医学实践转化的基础设施
- 批准号:
17200029 - 财政年份:2005
- 资助金额:
$ 32.94万 - 项目类别:
Grant-in-Aid for Scientific Research (A)
Animal experimentation and cardiac phenotyping of transgenic mouse models
转基因小鼠模型的动物实验和心脏表型分析
- 批准号:
13327687 - 财政年份:2005
- 资助金额:
$ 32.94万 - 项目类别:
Research Units














{{item.name}}会员




